KGM Receives Blue Rating of PROPER Audit from Ministry of Environmental and Forestry for 2nd Time
After successfully getting the 1st BLUE rating of PROPER environment audit of 2020-2021, at the end of 2022, KGM received their 2nd time of BLUE rating of PROPER. It shows that KGM was committed to implementing good practices in environmental management e.g. waste water management, hazardous waste management, and air emission control, including water conservation and renewable energy.
With the support of all employees and management, KGM always strives to maintain these achievements and aims to achieve the Green PROPER target in the future.
KGM at a Glance
Kalbio Global Medika (KGM) is one of the first and the pioneer of biopharmaceuticals in Indonesia, established in 2014 and inaugurated officially in 2018 by the President of the Republic of Indonesia, Ir. Joko Widodo. KGM is part of the Kalbe Group, a subsidiary of PT Kalbe Genexine Biologics (KGbio), which is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside US/Canada, Western Europe, and China. KGM is an Innovative CDMO, equipped with CMC and scale-up capabilities plugged into Boston biotech ecosystem and state-of-the-art facility to enhance efficiency and productivity. With API manufacturing, formulation, fill and finish capabilities of biosimilar and novel biologics, averaging 10 million units of syringes, cartridges, and vials, KGM supplies local and international markets.